Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma
<p>Abstract</p> <p>Background</p> <p>Although numerous chemotherapeutic agents have been tested, the role of systemic chemotherapy for hepatocellular carcinoma (HCC) has not been clarified. New therapeutic strategies are thus needed to improve outcomes, and we designed...
Main Authors: | Bang Soo-Mee, Lee Jeong, Park Yeon, Kim Ju, Kim Sun, Kwon Oh, Kwon So, Han Sang, Lee Yuna, Park Se, Cho Eun, Shin Dong, Lee Jae |
---|---|
Formato: | Artigo |
Idioma: | English |
Publicado em: |
BMC
2006-01-01
|
Colecção: | BMC Cancer |
Acesso em linha: | http://www.biomedcentral.com/1471-2407/6/3 |
Registos relacionados
-
Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer.
Por: Jieun Lee, et al.
Publicado em: (2017-01-01) -
Metronomic capecitabine versus doxorubicin in advanced hepatocellular carcinoma
Por: Gehan Abd Elatti Khedr, et al.
Publicado em: (2016-06-01) -
Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial
Por: Lee Jae, et al.
Publicado em: (2005-02-01) -
Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell Carcinoma
Por: Ming-Chun Ma, et al.
Publicado em: (2014-01-01) -
Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)
Por: Min‐Hee Ryu, et al.
Publicado em: (2023-04-01)